vs
Side-by-side financial comparison of GENCOR INDUSTRIES INC (GENC) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
GENCOR INDUSTRIES INC is the larger business by last-quarter revenue ($23.6M vs $18.6M, roughly 1.3× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 14.6%, a 51.1% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -25.0%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -23.9%).
Gencor Industries Inc is a leading manufacturer of heavy construction and infrastructure equipment, specializing in asphalt production plants, thermal combustion systems, and supporting road-building machinery. It primarily serves North American and global construction markets, supplying products to both public sector infrastructure projects and private commercial construction operators.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
GENC vs SCYX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.6M | $18.6M |
| Net Profit | $3.4M | $12.3M |
| Gross Margin | 28.7% | — |
| Operating Margin | 13.2% | 56.3% |
| Net Margin | 14.6% | 65.7% |
| Revenue YoY | -25.0% | 1808.5% |
| Net Profit YoY | -9.8% | 376.5% |
| EPS (diluted) | $0.23 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.6M | $18.6M | ||
| Q3 25 | $18.8M | $334.0K | ||
| Q2 25 | $27.0M | $1.4M | ||
| Q1 25 | $38.2M | $257.0K | ||
| Q4 24 | $31.4M | $977.0K | ||
| Q3 24 | $20.9M | $660.0K | ||
| Q2 24 | $25.6M | $736.0K | ||
| Q1 24 | $40.7M | $1.4M |
| Q4 25 | $3.4M | $12.3M | ||
| Q3 25 | $1.9M | $-8.6M | ||
| Q2 25 | $3.8M | $-6.9M | ||
| Q1 25 | $6.1M | $-5.4M | ||
| Q4 24 | $3.8M | — | ||
| Q3 24 | $1.5M | $-2.8M | ||
| Q2 24 | $2.6M | $-14.5M | ||
| Q1 24 | $6.2M | $411.0K |
| Q4 25 | 28.7% | — | ||
| Q3 25 | 24.2% | — | ||
| Q2 25 | 26.5% | — | ||
| Q1 25 | 29.7% | — | ||
| Q4 24 | 27.6% | — | ||
| Q3 24 | 25.6% | — | ||
| Q2 24 | 23.9% | — | ||
| Q1 24 | 30.3% | — |
| Q4 25 | 13.2% | 56.3% | ||
| Q3 25 | -1.2% | -2516.5% | ||
| Q2 25 | 11.6% | -701.0% | ||
| Q1 25 | 17.0% | -3350.2% | ||
| Q4 24 | 14.7% | — | ||
| Q3 24 | 5.9% | -1563.6% | ||
| Q2 24 | 7.8% | -1255.0% | ||
| Q1 24 | 17.4% | -692.5% |
| Q4 25 | 14.6% | 65.7% | ||
| Q3 25 | 10.2% | -2572.2% | ||
| Q2 25 | 14.2% | -504.8% | ||
| Q1 25 | 16.0% | -2097.7% | ||
| Q4 24 | 12.1% | — | ||
| Q3 24 | 6.9% | -425.5% | ||
| Q2 24 | 10.0% | -1964.4% | ||
| Q1 24 | 15.3% | 29.9% |
| Q4 25 | $0.23 | $0.25 | ||
| Q3 25 | $0.13 | $-0.17 | ||
| Q2 25 | $0.26 | $-0.14 | ||
| Q1 25 | $0.42 | $-0.11 | ||
| Q4 24 | $0.26 | — | ||
| Q3 24 | $0.10 | $-0.06 | ||
| Q2 24 | $0.17 | $-0.30 | ||
| Q1 24 | $0.42 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $147.7M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $215.2M | $49.4M |
| Total Assets | $228.9M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $147.7M | $40.0M | ||
| Q3 25 | $136.3M | $37.9M | ||
| Q2 25 | $136.0M | $44.8M | ||
| Q1 25 | $143.7M | $40.6M | ||
| Q4 24 | $130.1M | $59.3M | ||
| Q3 24 | $115.4M | $68.8M | ||
| Q2 24 | $116.6M | $73.0M | ||
| Q1 24 | $117.1M | $80.2M |
| Q4 25 | — | — | ||
| Q3 25 | $0 | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $215.2M | $49.4M | ||
| Q3 25 | $211.8M | $36.4M | ||
| Q2 25 | $209.9M | $44.5M | ||
| Q1 25 | $206.1M | $50.5M | ||
| Q4 24 | $200.0M | $55.1M | ||
| Q3 24 | $196.1M | $58.5M | ||
| Q2 24 | $194.7M | $60.4M | ||
| Q1 24 | $192.1M | $74.1M |
| Q4 25 | $228.9M | $59.0M | ||
| Q3 25 | $222.6M | $51.1M | ||
| Q2 25 | $220.2M | $60.7M | ||
| Q1 25 | $223.9M | $67.9M | ||
| Q4 24 | $218.2M | $90.6M | ||
| Q3 24 | $208.1M | $99.0M | ||
| Q2 24 | $201.8M | $107.8M | ||
| Q1 24 | $206.0M | $118.3M |
| Q4 25 | — | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.1M | $18.4M |
| Free Cash FlowOCF − Capex | $10.1M | — |
| FCF MarginFCF / Revenue | 43.0% | — |
| Capex IntensityCapex / Revenue | 4.1% | — |
| Cash ConversionOCF / Net Profit | 3.23× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $-3.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.1M | $18.4M | ||
| Q3 25 | $-275.0K | $-8.7M | ||
| Q2 25 | $-23.9M | $-7.5M | ||
| Q1 25 | $12.4M | $-7.5M | ||
| Q4 24 | $14.8M | $-24.0M | ||
| Q3 24 | $-3.2M | $765.0K | ||
| Q2 24 | $-1.0M | $-10.9M | ||
| Q1 24 | $11.7M | $-4.0M |
| Q4 25 | $10.1M | — | ||
| Q3 25 | $-1.3M | — | ||
| Q2 25 | $-24.4M | — | ||
| Q1 25 | $12.3M | — | ||
| Q4 24 | $14.5M | — | ||
| Q3 24 | $-3.3M | — | ||
| Q2 24 | $-1.4M | — | ||
| Q1 24 | $11.7M | — |
| Q4 25 | 43.0% | — | ||
| Q3 25 | -6.8% | — | ||
| Q2 25 | -90.4% | — | ||
| Q1 25 | 32.2% | — | ||
| Q4 24 | 46.1% | — | ||
| Q3 24 | -15.8% | — | ||
| Q2 24 | -5.6% | — | ||
| Q1 24 | 28.7% | — |
| Q4 25 | 4.1% | — | ||
| Q3 25 | 5.4% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 1.0% | — | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | 3.23× | 1.50× | ||
| Q3 25 | -0.14× | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | 2.04× | — | ||
| Q4 24 | 3.88× | — | ||
| Q3 24 | -2.22× | — | ||
| Q2 24 | -0.41× | — | ||
| Q1 24 | 1.87× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GENC
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
